CA3146477A1 - Use of sepiapterin and metabolites thereof to treat radiation exposure - Google Patents

Use of sepiapterin and metabolites thereof to treat radiation exposure Download PDF

Info

Publication number
CA3146477A1
CA3146477A1 CA3146477A CA3146477A CA3146477A1 CA 3146477 A1 CA3146477 A1 CA 3146477A1 CA 3146477 A CA3146477 A CA 3146477A CA 3146477 A CA3146477 A CA 3146477A CA 3146477 A1 CA3146477 A1 CA 3146477A1
Authority
CA
Canada
Prior art keywords
mir
subject
radiation
administering
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3146477A
Other languages
English (en)
French (fr)
Inventor
Eleonora MEZZAROMA
Christopher RABENDER
Ross MIKKELSEN
Vasily YAKOVLEV
Neil Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
PTC Therapeutics MP Inc
Original Assignee
Virginia Commonwealth University
PTC Therapeutics MP Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University, PTC Therapeutics MP Inc filed Critical Virginia Commonwealth University
Publication of CA3146477A1 publication Critical patent/CA3146477A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA3146477A 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure Pending CA3146477A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
US62/882,937 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Publications (1)

Publication Number Publication Date
CA3146477A1 true CA3146477A1 (en) 2021-02-11

Family

ID=72148243

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3146477A Pending CA3146477A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Country Status (21)

Country Link
US (1) US12667569B2 (cg-RX-API-DMAC10.html)
EP (2) EP4454712A3 (cg-RX-API-DMAC10.html)
JP (2) JP7642611B2 (cg-RX-API-DMAC10.html)
CN (2) CN119837879A (cg-RX-API-DMAC10.html)
AU (1) AU2020324435B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022002029A2 (cg-RX-API-DMAC10.html)
CA (1) CA3146477A1 (cg-RX-API-DMAC10.html)
DK (1) DK4009978T3 (cg-RX-API-DMAC10.html)
ES (1) ES2994060T3 (cg-RX-API-DMAC10.html)
FI (1) FI4009978T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241653T1 (cg-RX-API-DMAC10.html)
HU (1) HUE069012T2 (cg-RX-API-DMAC10.html)
IL (1) IL290321B2 (cg-RX-API-DMAC10.html)
LT (1) LT4009978T (cg-RX-API-DMAC10.html)
MX (1) MX2022001535A (cg-RX-API-DMAC10.html)
PL (1) PL4009978T3 (cg-RX-API-DMAC10.html)
PT (1) PT4009978T (cg-RX-API-DMAC10.html)
RS (1) RS66096B1 (cg-RX-API-DMAC10.html)
SI (1) SI4009978T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202500089T1 (cg-RX-API-DMAC10.html)
WO (1) WO2021026247A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
WO2005048926A2 (en) * 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
CA2545968C (en) 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
CN101132776A (zh) 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
KR20160065998A (ko) 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
JP5066756B2 (ja) 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
JP6084967B2 (ja) 2012-05-07 2017-02-22 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
JP2016530333A (ja) * 2013-09-13 2016-09-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 放射線の影響から防護するため及び放射線の影響を緩和するための組成物の調製及び使用
CN114306208A (zh) * 2014-10-02 2022-04-12 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗的用途
WO2018019931A1 (en) 2016-07-29 2018-02-01 Dipharma S.A. Pharmaceutical composition kit comprising sapropterin dihydrochloride
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) * 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
CA3165636A1 (en) 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
IL305037A (en) 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
AR127191A1 (es) 2021-09-29 2023-12-27 Ptc Therapeutics Inc Composición farmacéutica de sepiapterina

Also Published As

Publication number Publication date
EP4009978A1 (en) 2022-06-15
EP4454712A2 (en) 2024-10-30
SMT202500089T1 (it) 2025-03-12
ES2994060T3 (en) 2025-01-16
IL290321B2 (en) 2026-08-01
US12667569B2 (en) 2026-06-30
US20220273661A1 (en) 2022-09-01
EP4454712A3 (en) 2025-01-01
CN114555090A (zh) 2022-05-27
IL290321A (en) 2022-04-01
PT4009978T (pt) 2024-11-05
HRP20241653T1 (hr) 2025-04-25
PL4009978T3 (pl) 2025-02-24
JP7642611B2 (ja) 2025-03-10
AU2020324435B2 (en) 2026-03-19
LT4009978T (lt) 2024-11-25
RS66096B1 (sr) 2024-11-29
JP2022543655A (ja) 2022-10-13
BR112022002029A2 (pt) 2022-06-07
FI4009978T3 (fi) 2024-11-01
IL290321B1 (en) 2026-04-01
CN119837879A (zh) 2025-04-18
EP4009978B1 (en) 2024-09-25
MX2022001535A (es) 2022-03-04
AU2020324435A1 (en) 2022-02-24
HUE069012T2 (hu) 2025-02-28
CN114555090B (zh) 2024-12-17
SI4009978T1 (sl) 2025-03-31
WO2021026247A1 (en) 2021-02-11
JP2025098011A (ja) 2025-07-01
DK4009978T3 (da) 2024-10-14

Similar Documents

Publication Publication Date Title
AU2020324435B2 (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
EP3054952B1 (en) Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
EP1807083B1 (en) Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
AU2020200585A1 (en) Benzoquinone Derivative E3330 in Combination with Chemotherapeutic Agents for the Treatment of Cancer and Angiogenesis
Wang et al. The roles of oxidative stress and Beclin-1 in the autophagosome clearance impairment triggered by cardiac arrest
JP2018507244A (ja) 肺線維症の治療のためのアンギオテンシンii受容体作動薬
US20090318534A1 (en) Methods and compositions for the treatment of skin diseases and disorders
JP7854389B2 (ja) Klk5/7デュアル阻害剤としてのベンゾキサジノン化合物
JP2024133735A (ja) Iv型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
HK40118407A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
HK40075560A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
HK40075560B (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
EA048135B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
EA052521B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
CN111166756B (zh) 20(S)-人参皂苷-Rg3在逆转胶质瘤细胞对化疗药物的耐药性中的用途
CN101432000B (zh) 用于变应性眼病或变应性鼻病的包含三环性三唑并苯并氮杂*衍生物的预防剂或治疗剂
TW202143994A (zh) 環孢素類似物於治療纖維化之用途
EP4545076A1 (en) Lat1 selective inhibitors for use in the treatment of adverse ventricular -remodelling and of heart failure
WO1998051313A1 (fr) Remedes contre les yeux secs
RU2831430C1 (ru) Соединения бензоксазинона в качестве двойных ингибиторов klk5/7
WO2022195579A1 (en) Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
HK40059411A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
EA046794B1 (ru) Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240806

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250723

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250723

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250806

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: T-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260723

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: T-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260723